European researchers discovered novel angiogenic targets that could be exploited therapeutically for the treatment of retinal degeneration.
Age-related macular degeneration (AMD) is a retinal disease characterised by central vision loss due to the formation of new vessels. As a result, existing therapies aim to stop localised neovascularisation by inhibiting vascular endothelial growth factor (VEGF). However, retreatment is often necessary as the phenomenon recurs.
Further details: Novel therapies for retinal degeneration